RGEN News

Key Factors

Recent Updates

Catalyst

RGEN's fundamental factors such as PB-ROE, Cash-MV, and Gross profit margin indicate strong profitability and valuation metrics.
Analysts have rated RGEN as Strong Buy, showing some institutional optimism despite divergent views.

Risk

Technical indicators show a volatile market state for RGEN with more bearish signals (2 bearish vs 0 bullish) dominating recent patterns.
Fund flow trends show negative net inflow for Small, Medium, and Large order sizes, suggesting lack of support from smaller to mid-sized investors.
Market expectations for RGEN tend to be pessimistic as per analyst consensus and recent ratings.

Generated at21:0702/06/2026by

Aime

Newswire

15:19

Repligen Triggers MACD Death Cross, Bollinger Bands Narrowing on 15min Chart

19:45

Repligen Corp. Shares Cross Below 200-Day Moving Average

12:03

Repligen's 15-Minute Chart Triggers KDJ Golden Cross, Bullish Marubozu Formation

09:48

Repligen's 15min chart triggers RSI Oversold and KDJ Golden Cross.

09:33

Repligen's 15min chart shows MACD Death Cross, Bollinger Bands Narrowing, KDJ Death Cross.

About RGEN

Charts

SectorBiological Technology

Established Date--

Listing Date06/05/1986

ExchangeNASDAQ Stock Exchange

Full-time Employees1778

Fiscal Year Ends31/12

Websitewww.repligen.com

Security TypeCommon stock

Office address41 Seyon Street , Bldg. 1 , Suite 100 , Waltham , MA 02453

Business

Introduction

Repligen Corporation is a leader in supplying key biopharmaceutical products. The protein A produced by the company provides long-term supply, long-term contracts for important life science research companies, and is also sold directly to end users in the pharmaceutical processing chain. The company provides professional biological research and development products to SecreFlo's latest drug, which has submitted an application to the US Food and Drug Administration and has received priority testing, and the company has submitted a marketing authorization to the European drug regulatory agency. SecreFlo is a company that develops new imaging agents for synthetic human hormone drugs for the diagnosis of pancreatitis and a variety of potential pancreatic diseases. The company conducts two early research projects on rare diseases of the central nervous system, Friedrich's dyskinesia and spinal muscular atrophy have entered the first phase of clinical trials. In addition, the company has obtained an additional license for intellectual property from Bristol-Myers Squibb, the company's patent rights for the real-price sale of the drug abatacept in the United States. The company was established in May 1981.